An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma

por Lorenzi, Maria, Arndorfer, Stella, Aguiar-Ibañez, Raquel, Scherrer, Emilie, Liu, Frank Xiaoqing, Krepler, Clemens
Publicado 2019

Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina

por Wurcel, Victoria, Scherrer, Emilie, Aguiar-Ibanez, Raquel, Altuna, Juan Ignacio, Carabajal, Fernando, Jain, Shrishti, Baluni, Gargi
Publicado 2021

Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients

por Aguiar-Ibáñez, Raquel, Scherrer, Emilie, Grebennik, Dmitri, Cook, John, Bagga, Shalini, Sawhney, Baanie, Khandelwal, Anvi, Soefje, Scott A.
Publicado 2023

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

por Loong, Herbert H., Wong, Carlos K. H., Leung, Linda K. S., Tan, S. C., Jen, Jason, Lee, Mary Y. K., Aguiar-Ibáñez, Raquel, Wang, Jingshu
Publicado 2020

An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA

por Bensimon, Arielle G., Zhou, Zheng-Yi, Jenkins, Madeline, Song, Yan, Gao, Wei, Signorovitch, James, Krepler, Clemens, Scherrer, Emilie, Wang, Jingshu, Aguiar-Ibáñez, Raquel
Publicado 2020